Tocagen Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Employees
-
9
- Latest Deal Type
-
M&A
- Financing Rounds
-
13
- Investments
-
1
Tocagen General Information
Description
Tocagen Inc is a clinical-stage, cancer-selective gene therapy company. It is focused on developing product candidates designed to activate a patient's immune system against their own cancer from within. The company's cancer-selective gene therapy platform is built on retroviral replicating vectors, or RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Tocagen is developing product candidate, Toca 511 and Toca FC, for the treatment of recurrent high grade glioma, or HGG, a brain cancer with limited treatment options, low survival rates and, therefore, a significant unmet medical need. Geographically, the activities are carried out through United States.
Contact Information
Website
www.tocagen.comCorporate Office
- 4242 Campus Point Court
- Suite 600
- San Diego, CA 92121
- United States
Corporate Office
- 4242 Campus Point Court
- Suite 600
- San Diego, CA 92121
- United States
Tocagen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tocagen Comparisons
Industry
Financing
Details
Tocagen Competitors (25)
One of Tocagen’s 25 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Mustang Bio | Formerly VC-backed | Waltham, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
Tocagen Signals
Tocagen Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tocagen Acquisitions (1)
Tocagen’s most recent deal was a Reverse Merger with Forte Biosciences for . The deal was made on 16-Jun-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Forte Biosciences | 16-Jun-2020 | Reverse Merger | Drug Discovery |
Tocagen Exits (1)
Tocagen’s most recent exit was on 16-Jun-2020 from Forte Biosciences. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Forte Biosciences | 16-Jun-2020 | Completed |
|
Tocagen FAQs
-
When was Tocagen founded?
Tocagen was founded in 2007.
-
Where is Tocagen headquartered?
Tocagen is headquartered in San Diego, CA.
-
What is the size of Tocagen?
Tocagen has 9 total employees.
-
What industry is Tocagen in?
Tocagen’s primary industry is Drug Discovery.
-
Is Tocagen a private or public company?
Tocagen is a Private company.
-
What is the current valuation of Tocagen?
The current valuation of Tocagen is .
-
What is Tocagen’s current revenue?
The current revenue for Tocagen is .
-
How much funding has Tocagen raised over time?
Tocagen has raised $209M.
-
Who are Tocagen’s investors?
Accelerate Brain Cancer Cure, Biobrit, Foresite Capital, National Brain Tumor Society, and The American Brain Tumor Association are 5 of 6 investors who have invested in Tocagen.
-
Who are Tocagen’s competitors?
Aura Biosciences, Xenetic Biosciences, Iovance Biotherapeutics, Mustang Bio, and Kite Pharma are some of the 25 competitors of Tocagen.
-
When was Tocagen acquired?
Tocagen was acquired on 15-Jun-2020.
-
Who acquired Tocagen?
Tocagen was acquired by Forte Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process